AI methods for precision therapies
Our hope is that building tumor ecosystem representations and understanding the associated heterogeneity will allow us to predict disease progression and treatment response.
PROMETEX: metabolically-instructed therapy selection for prostate cancer
Together with Prof. Marianna Kruithof-de Julio from the Urogenus lab of the University of Bern and Prof. Theodore Alexandrov, Team Leader at EMBL Heidelberg, we are working on combining patient-derived organoids with single-cell metabolomics towards developing metabolically-instructed personalized prostate cancer therapies. Our project PROMETEX was recently awarded a Sinergia grant from the Swiss National Science Foundation.